Current Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States.
Journal Article Curr Oncol · November 16, 2024 Targeting tumor-specific molecular alterations has shown significant clinical benefit. Molecular tumor boards (MTBs) connect cancer patients with personalized treatments and clinical trials. However, rural cancer centers often have limited access to MTB ex ... Full text Link to item CiteComprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies Identifies Variants That Can Alter Clinical Practice.
Journal Article Hematol Rep · September 30, 2024 BACKGROUND: Comprehensive genomic profiling (CGP) is frequently adopted to direct the clinical care of myeloid neoplasms and solid tumors, but its utility in the care of lymphoid and histiocytic cancers is less well defined. METHODS: In this study, we aime ... Full text Link to item CitePirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.
Journal Article Lancet Haematol · September 2024 BACKGROUND: Richter transformation usually presents as an aggressive diffuse large B-cell lymphoma, occurs in up to 10% of patients with chronic lymphocytic leukaemia, has no approved therapies, and is associated with a poor prognosis. Pirtobrutinib has sh ... Full text Link to item CiteRecent Grants
A Prospective, Observational, Long-term Follow-up Study for Subjects who Previously Received Zamtocabtagene Autoleucel in a United States Miltenyi Biomedicine-Sponsored Clinical Study
Clinical TrialPrincipal Investigator · Awarded by Miltenyi Biomedicine · 2025 - 2030A Phase Ib/Ii, Open-Label, Multicenter Study With A Non-Randomized Stage Evaluating The Safety, Pharmacokinetics, And Efficacy Of Mosunetuzumab Plus Lenalidomide (+ Len), And A Randomized Stage Evaluating The Safety, Tolerability, And Pharmacokinetic
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2025 - 2030A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Clinical TrialPrincipal Investigator · Awarded by BeOne Medicines USA, Inc. · 2025 - 2030View All Grants
Education, Training & Certifications
Duke University ·
2006
M.D.